Autolus Therapeutics plc — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; the filing does not provide a clear set of standalone Q4 2019 financial results. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars, while the company’s functional currency is pounds sterling.
Business context
Autolus is a clinical-stage biotechnology company developing engineered T-cell therapies for cancer. It had no approved products and generated no product sales revenue. Grant income was its only reported revenue. Its principal programs included AUTO1 for acute lymphoblastic leukemia, AUTO3 for DLBCL, AUTO4 for T-cell lymphoma, and programs in preclinical development.
Key financial metrics
| Metric | FY2019 | FY2018 comparable |
|---|---|---|
| Grant income | $2.9 million | $1.5 million |
| Research and development expense | $105.4 million | $48.3 million |
| General and administrative expense | $39.5 million | $27.3 million |
| Leasehold-improvement impairment | $4.1 million | None reported |
| Total operating expenses, net | $146.1 million | $74.1 million |
| Net loss | $123.8 million | $57.9 million |
| Income tax benefit | $15.2 million | $8.5 million |
The FY2018 comparison is unaudited and assembled from the nine months ended September 30, 2018 and the three-month transition period ended December 31, 2018. Operating or gross margins are not meaningful because Autolus had no product sales.
- Cash and liquidity: Cash was $210.6 million at December 31, 2019, versus $217.5 million a year earlier. Working capital was $224.3 million; total assets were $303.5 million and total liabilities were $48.7 million.
- Cash flow: Operating activities used $101.5 million; investing activities used $18.7 million; financing activities provided $108.9 million. Cash and restricted cash decreased by $6.1 million, after a positive $5.2 million exchange-rate effect.
- Debt and leases: The filing reports no material financing commitments such as credit lines or guarantees. At year-end, lease liabilities totaled $26.2 million, including $2.5 million current and $23.7 million non-current. A signed Rockville lease not yet commenced was excluded from that liability and carries about $57.9 million of undiscounted future minimum payments.
- Capital and share count: The April 2019 offering generated $108.8 million net proceeds; 44,983,006 ordinary shares were outstanding at year-end. A January 2020 offering subsequently raised approximately $75.0 million net.
Material changes versus the prior comparable period
- Net loss more than doubled, from $57.9 million to $123.8 million, as total operating expenses increased by $71.9 million.
- R&D expense rose $57.1 million, reflecting increased staffing, clinical-program activity, facilities and manufacturing investment, and non-cash share-based compensation.
- G&A expense increased $12.2 million. FY2019 also included a $4.1 million impairment after Autolus discontinued the fit-out of its Enfield manufacturing facility.
- Operating cash use increased to $101.5 million. Cash was lower year over year despite the April 2019 equity financing.
- Autolus discontinued AUTO2 development and redirected multiple-myeloma efforts to AUTO8. It also decided not to continue AUTO3 development in pediatric ALL, focusing there on AUTO1 and AUTO1NG.
Outlook, commentary, and material risks
- Management expected significant expenses and losses to continue and said year-end cash would fund current and planned operating and capital requirements for at least 12 months from the report date. The January 2020 offering added approximately $75.0 million net after year-end.
- Planned development included a potential Phase 2 AUTO1 adult ALL trial in 2020; AUTO8’s first multiple-myeloma trial in 2020; and AUTO6NG clinical trials expected to begin in 2020. The company also anticipated an initial allogeneic application entering clinical testing in Q4 2020. These are forward-looking plans, not assured outcomes.
- Reported clinical findings were preliminary and based on small patient numbers. AUTO1 trials included serious events, including deaths and persistent cytopenias; the company reported that some deaths were disease- or infection-related, and one CARPALL death was considered treatment-related. AUTO3 results were also preliminary; no treatment-related deaths were reported in the cited DLBCL trial update.
- Key risks include clinical failure or delay, serious treatment toxicities, patient recruitment, manufacturing reliability and scale-up, reliance on external facilities and suppliers, regulatory approval, competition, intellectual-property disputes, and the need for additional financing. Management stated current cash would not fund any candidate through regulatory approval.
- Autolus discontinued the Enfield facility fit-out but remained responsible for a long-term lease and was seeking to sublease or assign it. Total operating lease obligations disclosed at year-end were $34.4 million, excluding the not-yet-commenced Rockville lease.
- Foreign-exchange movements affect reported results; the company had no currency hedges in place. It also relied on U.K. R&D tax credits, whose availability and realization are subject to eligibility and other restrictions.
Most important facts for investors to verify
- Distinguish the full-year 2018 comparison from the filing’s separately presented three-month transition-period figures; confirm the calculation basis when comparing periods.
- Review the audited financial statements and cash-flow details, including the scale of non-cash share-based compensation and the cash required to fund operations.
- Confirm the effect of the January 2020 offering on cash runway, share count, and dilution; the stated runway estimate was based on management assumptions.
- Track clinical-trial updates, enrollment, durability, adverse events, and regulatory feedback; treat early efficacy and survival estimates as preliminary.
- Assess manufacturing capacity and supply-chain execution, the Enfield lease exposure, and the future Rockville lease commitment.
- Monitor the status and collectability of U.K. R&D tax credits, as well as patent and licensing risks, including potential U.S. patent constraints affecting AUTO1.